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Overt immediate hemolytic 
transfusion reaction attributable 
to anti-Wra
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Wra is a low-prevalence antigen.  Anti-Wra is a relatively com-
mon antibody present in approximately 1 in 100 healthy blood 
donors.  Anti-Wra is reported to cause different degrees of 
hemolysis in transfusion and in HDN, ranging from benign to 
severe.  This report describes an acute overt hemolytic transfu-
sion reaction in a patient whose serum contained anti-Wra and 
who received a Wr(a+) RBC component.  Immunohematology 
2008;24:113–115.
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In 1953, Holman1 described an RBC antibody, 
which was named anti-Wra, that detects a rare anti-
gen, Wra.  In 1995, Wra was shown to be part of the 
Diego system,2 which is controlled by the SLC4A1 
(DI)3 gene on chromosome 17.  The prevalence of 
Wra is 1 in 1000 in the White British population4 and 
1 in 785 in the White Spanish population.5  Although 
far fewer people have been tested, Wra has not been 
found in Blacks, Australian Aborigines, natives of 
New Guinea, or other non-European populations.2 
Wra antigens on RBCs are resistant to treatment with 
proteolytic enzymes, including trypsin, α-chymo-
trypsin, papain, and pronase, or neuraminidase 
and to treatment with 2-aminoethylisothiouronium 
bromide.2
Anti-Wra is a relatively common antibody with an 
incidence of 1.06 to 4.3 percent in the sera of healthy 
individuals and is more frequent (4 to 10%) in patients 
with autoimmune hemolytic anemia and in pregnant 
and recently postpartum women.4,5  Anti-Wra can be 
isotype IgM reactive at less than 37°C or IgG reactive 
by IAT.  Wra is well developed in newborns; however, 
HDN attributable to anti-Wra is very rare.6–8  Although 
anti-Wra is common,2 it is seldom detected in contem-
porary antibody-screening tests as Wr(a+) RBCs are 
not present on commercial reagent screening RBCs.9 
The routine use of the immediate spin compatibility 
test and computer matching of units for patients in 
whom antibody screening tests are negative may 
result in some patients with anti-Wra receiving Wr(a+) 
RBCs.2  However, the probability of incompatibility 
and hemolytic transfusion reaction is very low.  This 
report describes an acute overt hemolytic transfusion 
reaction in a transfusion-dependent adult whose 
serum was nonreactive with reagent screening RBCs 
and who received a transfusion of Wr(a+) packed RBCs 
that were compatible at immediate spin.  Because of 
the low probability of a transfusion reaction attribut-
able to the presence of a low-prevalence antigen, an 
immediate spin or computer crossmatched transfu-
sion can be considered safe.10,11  However, if during 
the transfusion there are any complaints from the 
patient or changes in vital signs, the transfusion must 
be terminated immediately.
Case Report
An 83-year-old White man with large granular 
T-cell lymphoproliferative disorder was diagnosed 
with aplastic anemia and became transfusion-depen-
dent.  The patient received 17 units of packed RBCs 
during the 3 months before the present episode.  The 
patient had presented for transfusion with Hb of 8.7 
g/dL.  His RBCs typed as group A, D+; the auto- 
control and screening tests for unexpected antibod-
ies by IAT were negative.  One group A, D+ RBC 
unit was crossmatched using the immediate spin 
technique and found to be compatible.  During trans-
fusion of the RBC unit, the patient complained of 
chills and rigors.  He received an antipyretic and the 
transfusion was continued.  Posttransfusion hemo-
globin was not measured.  The patient returned in 2 
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days feeling profoundly weak, with a blood pressure 
of 84/50 mm Hg (pretransfusion blood pressure was 
135/86 mm Hg).  His Hb had fallen to 7.8 g/dL, his 
creatinine rose from 2.2 mg/dL before transfusion to 
3.3 mg/dL, his LDH level was elevated at 681 IU/L, 
his total bilirubin was increased from 0.5 mg/dL to 
2.3 mg/dL, and his haptoglobin was low normal. 
Troponin was elevated, which is consistent with a 
silent myocardial infarction.  His DAT was negative 
and no elution was performed.  The ABO group of 
the transfused unit was reconfirmed, and a serologic 
workup with panel RBCs was negative.  Other pos-
sible causes of hemolysis, including medication, were 
excluded.  When IAT crossmatches were performed 
on the retained donor blood segments with the 
patient’s pre- and posttransfusion serum, both were 
strongly positive (3+).  The specimens were sent to 
a reference laboratory.  The patient received diuret-
ics and also received an IAT crossmatch compatible 
RBC unit and was discharged on the fourth day of 
hospitalization.
Material and Methods
ABO and D typing was performed on the 
patient’s samples using standard commercial re-
agents according to the manufacturer’s instructions 
(Immucor/Gamma, Norcross, GA).  The DAT was 
performed using polyspecific antihuman globulin 
(Immucor/Gamma) and monospecific anti-IgG and 
anti-C3d (Immucor, Norcross, GA).  Screening for 
unexpected RBC antibodies was performed by us-
ing commercially prepared reagent RBCs (Immucor). 
The patient’s serum was tested against panels of 
commercial reagent RBCs (Immucor) to determine 
antibody specificities.  BSA and PEG dissolved in 
a low-ionic-strength medium (PEG, Immucor) were 
used as enhancing agents.  Additional testing to 
characterize the low-prevalence antibody was per-
formed.  Serum was tested against selected RBCs 
known to possess low-prevalence antigens.  LISS and 
PEG (Immucor, Norcross, GA) were both used.  All 
testing was performed using standard tube tests.
Results
The patient’s RBCs typed as group A, D+, and 
his serum was nonreactive with reagent screening 
RBCs.  The initial immediate spin test was negative. 
However, when the patient’s serum was crossmatched 
by the IAT with RBCs from the transfused unit, a 
3+ reaction was obtained.  The DAT on RBCs from 
the posttransfusion sample was negative.  When IAT 
crossmatches were performed on the retained donor 
blood segments with the patient’s pre- and posttrans-
fusion serum, both were strongly positive (3+).  The 
specimens were sent to a reference laboratory (New 
York Blood Center, immunohematology laboratory). 
When the serum was tested against RBCs with low-
prevalence antigens, the Wr(a+) RBC samples reacted. 
No other unexpected antibodies were detected using 
IAT that included albumin, papain-modified RBCs, 
and PEG.  The Wra typing was performed using 
single-donor-source antibodies, and the RBCs from 
the donor unit were Wr(a+).
Discussion
Holman1 first described anti-Wra as a cause of 
HDN and named it after the family (Wright) in which 
it was found.  Later the antigen was assigned to the 
Diego blood group system.2  Anti-Wra is not uncom-
mon as a naturally occurring or secondary antibody 
to RBC transfusion or pregnancy.  Anti-Wra was 
found in 7.3 percent of pregnant women and 7.9 to 
10.2 percent of hospital patients without other RBC 
antibodies.4,5  Only the rare IgG anti-Wra may cause 
HDN.7
Despite the fact that the antibody could cause 
hemolysis in vitro, only one case of hemolytic trans-
fusion reaction in an adult patient attributable to 
anti-Wra was reported12 and an additional case was 
described as part of a survey.13
In the present case, the antibody screen was 
negative owing to the lack of Wra on the reagent 
RBCs.  In addition, the immediate spin crossmatch 
was compatible because of the IgG nature of the 
circulating antibody.  A transfusion reaction was 
noticed during the RBC transfusion but ignored as 
a trivial observation.  Two days later the patient 
presented with symptoms and laboratory evidence 
highly suggestive of a hemolytic transfusion reaction. 
However, his RBCs did not react in the DAT and an 
IAT crossmatch of pre- and posttransfusion serum 
with the remains of the RBC unit showed 3+ incom-
patibility.  The negative DAT may be attributable to 
the hemolysis of the donor RBCs during the 48 hours 
after transfusion.  The screening for a low-prevalence 
antigen and antibody showed that the patient has an 
IgG anti-Wra reactive by the IAT and the donor unit 
was Wr(a+).
The use of an immediate crossmatch may allow 
transfusion of incompatible RBCs.  Because the 
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prevalence of Wra is 1 in 1000, the occurrence of the 
antibody is 7 to 10 percent, and most of the antibody 
isotype is IgM, the probability of incompatibility and 
hemolytic transfusion reaction is calculated to be 7 
to 10 in 100,000.  As a result of this low probability 
of a transfusion reaction in patients with antibodies 
directed at low-prevalence antigens, an immediate 
spin transfusion can be considered safe.9–11  However, 
if during the transfusion any complaint from the pa-
tient or change of vital signs occurs, the transfusion 
must be terminated immediately.
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